Latest Articlesddd

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and Vemlidy from Gilead Sciences Succeed in Treating Chronic Hepatitis B Viral Infection

October 24, 2019 0

Spring Bank Pharmaceuticals, Gilead Sciences and HBV If Spring Bank Pharmaceuticals’ (SBPH) product inarigivir in combination …

This Past Week

October 22, 2019 0

The Week in Review #43 This Past Week After hearing hints about the trade war between …

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

October 21, 2019 0

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics (SGEN) announced positive topline results from …

Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today

October 17, 2019 0

Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders On October 9, 2019 Ionis Pharmaceuticals (IONS) announced …

Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

October 17, 2019 0

Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE …

Reata Pharmaceuticals’ Product Omaveloxolone Met the Trial Primary Endpoints in Treating Friedreich’s Ataxia

October 16, 2019 0

Reata Pharmaceuticals Omaveloxolone for Friedreich’s Ataxia On October 14, 2019 Reata Pharmaceuticals (RETA) announced the Part 2 …

RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

October 15, 2019 0

RegenxBio Rebounding RegenxBio (RGNX) has the viral vectors which could safely deliver genes into the cells. …

Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314

October 14, 2019 0

RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio (RGNX) announced interim …

Novartis: Plenty of Good News. See Also: Topics We Will Address in an Upcoming Week in Review

October 11, 2019 0

Stock Market Volatility  Stocks can move up and down for various reasons but not all of …

More News for Nektar Therapeutics

October 8, 2019 0

Nektar Therapeutics Announces Two Studies of NKTR-358 Nektar Therapeutics (NKTR) announced the initiation of two Phase 1b …

During the Departed Week

October 7, 2019 0

The Week in Review #42 During the Departed Week The week started with the market losing …

What Are We Experiencing Now?

October 4, 2019 0

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing …

Seattle Genetics’ Product Tucatinib Beats Agressive Colorectal Cancer. The Stock Price Soars

September 30, 2019 0

Seattle Genetics Stock Rally Seattle Genetics (SGEN) stock has rallied today. It gained around $10; trading …

Enanta Product EPD-305 Has Promising Results for the Treatment NASH

September 28, 2019 0

Enanta Positive Results of EPD-305 for NASH Enanta (ENTA) has positive results from the ARGON-1 Phase …

The Medicines Company: Improving Atherosclerotic Cardiovascular Diseases (ASCVD)

September 26, 2019 0

The Medicines Company ORION-10 Study for ASCVD The Medicines Company (MDCO) announced positive topline results from …

Could Incyte’s Ruxolitinib Cream Effectively Treat Vitiligo?

September 26, 2019 0

Vitiligo Vitiligo is a chronic autoimmune disease. The immune system attacks the pigment-producing melanocyte cells causing …

News from NKTR, BMY and MRK. See Also: Biotechs’ Bizarre Performances in Early Trading Hours Today

September 24, 2019 0

News from Nektar Nektar Therapeutics (NKTR) announced that new data from patients with metastatic triple-negative breast cancer, …

The Value of the Biotech Companies Continued

September 23, 2019 0

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A …

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

September 20, 2019 0

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come …

Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

September 17, 2019 0

Atara Biotherapeutics ATA188 for MS Atara Biotherapeutics (ATRA) announced the presentation of initial efficacy data as …